Siegfried and BioNTech Sign Contract for the Aseptic Fill & Finish of a COVID-19 Vaccine
The Siegfried Group (SIX: SFZN) announces that it has signed a cooperation and supply agreement with Biopharmaceutical New Technologies (BioNTech), a German immunotherapy company, for the large-scale filling and packaging of commercial quantities of BNT162b2, an innovative COVID-19 vaccine candidate. Following successful approval, the vaccine developed by BioNTech in cooperation with Pfizer, a US American pharmaceutical company, will be filled by Siegfried at its Hameln site from mid 2021 onwards.
Siegfried CEO Dr. Wolfgang Wienand: “We are proud to make an important contribution toward combatting the pandemic through this partnership, and we are determined to support BioNTech in the best possible way. As a leading CDMO company with a strong global manufacturing network, Siegfried is in a position to take on technologically demanding tasks at short notice and to quickly build up the necessary capacities.”
The BNT162b2 vaccination, jointly developed by BioNTech and Pfizer, is currently undergoing global pivotal clinical phase 2/3 trials. If the study is successful, it is planned to seek regulatory review in October 2020. For the aseptic filling and packaging ("fill & finish") of the vaccine, Siegfried will invest in a dedicated production line at its Hameln (Germany) site and provide special storage capacity. The first phase of the agreement will end 2022, with the shared intention to expand the cooperation into a strategic partnership between BioNTech and Siegfried.
Marianne Späne, Global Head Business Development & Sales at Siegfried: "We very much look forward toward the cooperation with this pioneer company for biopharmaceuticals. This contract, for which we will make full use of our technical capabilities and high quality standards, represents the first step for us toward a long-term partnership with further potential.”